• 1
    Luscombe C & Locarnini S. The mechanism of action of antiviral agents in chronic hepatitis B. Viral Hepatitis Reviews 1996; 2: 1 35.
  • 2
    Main J, Brown J, Howells C, Galassini R, Crossey M, Karayiannis P. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Viral Hepatitis 1996; 3: 211 15.
  • 3
    Dienstag JL, Perillo RPI, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 1995; 333: 1657 61.
  • 4
    Lai CL, Chien RN, Leung NWY et al. One year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998; 339: 61 7.
  • 5
    Todo S, Demetris AJ, Van Thiel D, Teperman L, Fun JJ, Stazl TE. Orthotopic liver transplanation for patients with hepatitis B virus-related disease. Hepatology 1991; 13: 619 26.
  • 6
    Devlin J, Smith HM, Drotman B, Tan KC, Williams R. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg positive liver recipients. J. Hepatol. 1994; 21: 204 10.
  • 7
    Samuel D, Bismuth A, Matthieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg positive patients. Lancet 1991: 337: 813 15.
  • 8
    Terrault NA, Zhou S, Combes C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327 33.
  • 9
    Angus P, Locarnini S, McCaughan GW, June R, Bowden S. Hepatitis B virus precore mutant infection is associated with severe recurrent disease following liver transplanatation. Hepatology 1995; 21: 14 18.
  • 10
    Nauman U, Protzer-Knolle U, Berg T et al. A pre-transplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti hepatitis B virus surface antigen immunoprophylaxis. Hepatology 1997; 26: 478 84.
  • 11
    McGory R, Ishitani M, Oliveira W et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunisation. Transplantation 1996; 61: 1358 64.
  • 12
    Adler R, Safadi R, Carco Y et al. Comparision of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Hepatology 1999; 29: 1299 1305.
  • 13
    Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212 15.
  • 14
    Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin Hepatology 1998; 28: 585 9.
  • 15
    McCaughan GW, Spencer J, Koorey D et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant associated infection. High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transplant Surg. 1999; 5: 512 19.
  • 16
    McCaughan GW, Koorey D, Spencer J et al. Prophylactic lamivudine and very low dose HBIG prevent HBV recurrence post liver transplant whilst rescue therapy with lamivudine is associated with significant resistance and graft loss. Hepatology 1998; 28: 263A.
  • 17
    Perrillo R, Jorge R, Dienstag J et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29: 1581 6.
  • 18
    Ling R, Mutimer D, Ahmed M, Boxall E, Elias E, Dusheiko G. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711 13.
  • 19
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kreteman NM, Tyrell DLJ. Mutation in HBV RNA-dependant DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714 17.
  • 20
    Allen MI, Deslauriers M, Andrews CW et al. Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 1670 7.
  • 21
    Leung NWY, Lai CL, Change TT et al. Three year lamivudine therapy in chronic HBV. J Hepatol. 1999; 30 (Suppl.): 59 (Abstract).
  • 22
    Boni T, Bertoletti A, Penna A et al. Lamivudine treatment can restore T-cell responsiveness in chronic hepatitis B. J. Clin. Invest. 1998; 102: 968 75.
  • 23
    Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 216 25.
  • 24
    Bartholomeusz A, Groenen LC, Locarnini SA. Clinical experience with famciclovir against hepatitis B virus. Intervirology 1997; 40: 337 42.
  • 25
    Nicoll A, Locarnini S, Chou ST, Smallwood R, Angus P. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo. J. Gastroenterol. Hepatol. 2000; 15: 304 10.
  • 26
    Freiman JS, Jilbert AR, Dixon RJ et al. Experimental duck hepatitis B virus infection: Pathology and evolution of hepatic and extrahepatic infection. Hepatology 1988; 8: 507 13.